Two studies were undertaken to determine a possible genetic basis for alterations in phospholipid metabolism in schizophrenia. Initial results demonstrated an association in 65 schizophrenics compared with a matched normal control population. A follow-up haplotype relative risk study of 44 triads (mother, father, affected offspring), confirmed the results seen in the association study. Results suggest that a genetic variant near the promotor region of the gene for cytosolic phospholipase A2, the rate-limiting enzyme in the synthesis of prostaglandins from arachidonic acid, is associated with schizophrenia.
Bibliographical noteFunding Information:
We thank Arturas Petronis, Mary Seeman, Astride Vicente, Patrick Massad and two anonymous reviewers for reviewing the manuscript. This study was supported by grants from the Medical Research Council of Canada, the Physician Services Incorporated Foundation, and Scotia Pharmaceuticals.
- Genetic association
- Genetic polymorphism
- Haplotype relative risk
- Phospholipase A